Nilogen Oncosystems Announces Partnership with Scailyte AG to Provide a Clinically Relevant Translational Platform Supporting the Development of Immuno-Oncology Therapies in Oncology Clinical Trials and Ultimately to Support Personalized Medicine for Patients
The joint platform will open up new paradigms in drug discovery and development through Nilogen Oncosystems’ unique 3D EXplore tumor technology that keeps the tumor microenvironment intact, and the ability of ScaiVision™ to detect complex, ultra-sensitive molecular signatures and predictive in biological samples.
“Nilogen Oncosystems’ ability to generate omics and multimodal data from every treatment option and for every patient is unique. This capability, coupled with Scailyte’s ability to unlock molecular information with single cell resolution, creates an unprecedented level of personalized information and precision. will not only change the way we discover and develop new therapies, but more importantly will save more lives,” said Juana Lucia Flores-CandieVP Strategy & Business Development at Scailyte.
“We are excited to work with Scailyte, as I believe our integrated solutions will not only help our BioPharma customers make faster, data-driven decisions throughout their drug development process, but will also enable us to do advancing precision medicine applications for the treatment of cancer patients,” said Soner AltiokMD, PhD, Scientific Director at Nilogen Oncosystems.
About Nilogen Oncosystems
Founded in 2013, Nilogen Oncosystems, LLC is an oncology drug development company with CLIA-certified facilities in Tampa, Florida. At Nilogen, we appreciate the complexity of cancer and use fresh patient tumor samples with an intact tumor immune microenvironment in our 3D-EXplore preclinical drug testing platform. This holistic approach allows us to develop integrated solutions for a better understanding of the molecular mechanisms of drug sensitivity and resistance. Our goal is to enable the development of more effective drugs and drug combinations and to reduce the costs and risks associated with clinical trials. Nilogen’s commitment to testing and personalizing cancer drug development is proven and delivering unparalleled results for its customers.
For more information, visit www.nilogen.com and connect on social media @LinkedIn.
Scailyte AG is a spin-off from ETH Zurich and combines single-cell technologies, high-quality datasets and machine learning methods to identify disease-specific biomarkers, with a focus on oncology and immunology. Scailyte’s proprietary, best-in-class data analysis platform, ScaiVision, combines multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical parameters, such as diagnosis of the disease, its progression, its severity, the response to treatment, in order to identify signatures of ultra-sensitive biomarkers. With single-cell resolution and AI-based approach, ScaiVision is the most powerful and advanced approach for accurate diagnosis and prediction of therapeutic response. Scailyte leverages an extensive network of senior clinicians to identify clinical indications with high unmet clinical need and collaborates with global pharmaceutical and biotech companies to translate new biomarkers into ultra-sensitive companion diagnostics (CDx) or assays IVD.
For more information, visit www.scailyte.com and connect on social networks @LinkedIn and @Twitter.